/PRNewswire/ Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused.
Women with MS who stop taking natalizumab during pregnancy are at a significantly increased risk of relapse-related disability up to 1 year after delivery, new research shows.